{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:57:22Z","timestamp":1790683042048,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40272-026-00764-3","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:11:48Z","timestamp":1785161508000},"page":"563-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["21\u2011Valent Pneumococcal Conjugate Vaccine V116 (CAPVAXIVE\u00ae): Pediatric First Approval"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-7391","authenticated-orcid":false,"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"4","key":"764_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41579-024-01116-z","volume":"23","author":"AR Narciso","year":"2025","unstructured":"Narciso AR, Dookie R, Nannapaneni P, et al. Streptococcus pneumoniae epidemiology, pathogenesis and control. Nat Rev Microbiol. 2025;23(4):256\u201371.","journal-title":"Nat Rev Microbiol"},{"key":"764_CR2","unstructured":"Centers for Disease Control and Prevention. Clinical overview of pneumococcal disease. 2026. https:\/\/www.cdc.gov\/pneumococcal\/hcp\/clinical-overview\/index.html. Accessed 13 Jul 2026."},{"issue":"1","key":"764_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2491855","volume":"21","author":"DC LaFon","year":"2025","unstructured":"LaFon DC. Evaluation of efficacy and effectiveness across the pneumococcal conjugate vaccine era. Hum Vaccin Immunother. 2025;21(1):2491855.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"764_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010013","volume":"7","author":"I Papadatou","year":"2019","unstructured":"Papadatou I, Tzovara I, Licciardi PV. The role of serotype-specific immunological memory in pneumococcal vaccination: current knowledge and future prospects. Vaccines. 2019;7(1):13.","journal-title":"Vaccines"},{"key":"764_CR5","unstructured":"European Medicines Agency. Capvaxive: summary of product characteristics. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/capvaxive-epar-product-information_en.pdf. Accessed 13 Jul 2026."},{"key":"764_CR6","unstructured":"US FDA. CAPVAXIVE\u00ae (pneumococcal 21-valent conjugate vaccine) injection, for intramuscular use: US prescribing information. 2026. https:\/\/www.fda.gov\/media\/179426\/download. Accessed 13 Jul 2026."},{"key":"764_CR7","unstructured":"European Medicines Agency. Capvaxive: EPAR - public assessment report. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/capvaxive-epar-public-assessment-report_en.pdf. Accessed 13 Jul 2026."},{"key":"764_CR8","doi-asserted-by":"crossref","unstructured":"Jagannath V, Pathirana J, Perez Yepes CA, et al. A phase 3, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-013) [poster presentation]. In: British Society for Antimicrobial Chemotherapy (BSAC) Spring Conference; London, UK. 2026.","DOI":"10.1080\/21645515.2026.2684089"},{"issue":"1","key":"764_CR9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063039","volume":"153","author":"I Yildirim","year":"2023","unstructured":"Yildirim I, Lapidot R, Shaik-Dasthagirisaheb YB, et al. Invasive pneumococcal disease after 2 decades of pneumococcal conjugate vaccine use. Pediatrics. 2023;153(1):e2023063039.","journal-title":"Pediatrics"},{"issue":"10","key":"764_CR10","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1016\/S2666-5247(22)00158-6","volume":"3","author":"SW Lo","year":"2022","unstructured":"Lo SW, Mellor K, Cohen R, et al. Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study. Lancet Microbe. 2022;3(10):e735\u201343.","journal-title":"Lancet Microbe."},{"issue":"4","key":"764_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01696-24","volume":"63","author":"L Dierckx","year":"2025","unstructured":"Dierckx L, Rodriguez-Ruiz JP, Ekinci E, et al. Pneumococcal genotype 23B1 as a driver of increased 23B serotype carriage, penicillin non-susceptibility, and invasive disease in Belgium: a retrospective analysis. J Clin Microbiol. 2025;63(4):e01696-24.","journal-title":"J Clin Microbiol"},{"key":"764_CR12","unstructured":"European Medicines Agency. Capvaxive: extension of indication variation assessment report. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/capvaxive-vr-0000294070-epar-assessment-report-variation_en.pdf. Accessed 13 Jul 2026."},{"key":"764_CR13","unstructured":"European Medicines Agency. Capvaxive: procedural steps taken and scientific information after the authorisation. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/capvaxive-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 13 Jul 2026."},{"key":"764_CR14","unstructured":"US FDA. Approval letter - CAPVAXIVE. 2026. https:\/\/www.fda.gov\/media\/193219\/download?attachment. Accessed 13 Jul 2026."},{"key":"764_CR15","unstructured":"Ligand Pharmaceuticals. Ligand\u2019s collaborator Merck announces V116, an investigational, 21-valent pneumococcal conjugate vaccine specifically designed for adults, met key immunogenicity and safety endpoints in two phase 3 trials [media release]. 27 Jul 2023. https:\/\/investor.ligand.com\/news-and-events\/press-releases\/news-details\/2023\/Ligands-Collaborator-Merck-Announces-V116-An-Investigational-21-Valent-Pneumococcal-Conjugate-Vaccine-Specifically-Designed-For-Adults-Met-Key-Immunogenicity-And-Safety-Endpoints-In-Two-Phase-3-Trials\/default.aspx."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00764-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00764-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00764-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:17:05Z","timestamp":1790680625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00764-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00764-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt\u00a0Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}